

Edgar Filing: ROSETTA INPHARMATICS INC - Form SC 13D/A

ROSETTA INPHARMATICS INC
Form SC 13D/A
July 20, 2001

1

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(AMENDMENT NO. 1)

Rosetta Inpharmatics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

777777103

(CUSIP Number)

Celia A. Colbert
Vice President, Secretary
and Assistant General Counsel
Merck & Co., Inc.
One Merck Drive
Whitehouse Station,
New Jersey 08889-0100
(908) 423-1000

with a copy to:
Gary P. Cooperstein
Fried, Frank, Harris, Shriver & Jacobson
One New York Plaza
New York, NY 10004-1980
(212) 859-8000

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

July 19, 2001

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section

Edgar Filing: ROSETTA INPHARMATICS INC - Form SC 13D/A

of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

2

SCHEDULE 13D

CUSIP No. 777777103

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

MERCK & CO., INC. - 22-1109110

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐

(b) ☐

NOT APPLICABLE

3 SEC USE ONLY

4 SOURCE OF FUNDS (SEE INSTRUCTIONS)

00, WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)

☐

NOT APPLICABLE

6 CITIZENSHIP OR PLACE OF ORGANIZATION

NEW JERSEY

NUMBER OF 7 SOLE VOTING POWER

SHARES SEE ITEM 5

BENEFICIALLY 8 SHARED VOTING POWER

OWNED BY SEE ITEM 5

EACH 9 SOLE DISPOSITIVE POWER

REPORTING SEE ITEM 5

PERSON 10 SHARED DISPOSITIVE POWER

WITH -0-

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

SEE ITEM 5

12 CHECK BOX IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

☐

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

100%

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

Edgar Filing: ROSETTA INPHARMATICS INC - Form SC 13D/A

3

This Amendment No. 1 to Schedule 13D (the "Amendment") amends and supplements the Schedule 13D originally filed on May 21, 2001 (the "Schedule 13D") by Merck & Co., Inc., a New Jersey corporation ("Merck"), relating to (i) the merger (the "Merger") of Coho Acquisition Corp., a Delaware corporation and a direct wholly-owned subsidiary of Merck ("Merger Sub") with and into Rosetta Inpharmatics, Inc., a Delaware corporation ("Rosetta"), pursuant to the Agreement and Plan of Merger, dated as of May 10, 2001 between Merck, Merger Sub and Rosetta (the "Merger Agreement") and (ii) certain transactions entered into in connection with the Merger Agreement and described below.

Except as amended by this Amendment, there has been no change in the information previously reported on the Schedule 13D.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

See Item 5.

ITEM 4. PURPOSE OF TRANSACTION.

See Item 5.

ITEM 5. INTERESTS IN SECURITIES OF THE ISSUER.

Item 3, Item 4 and Items 5(a)-(c) are hereby amended and supplemented by the addition of the following information:

On July 19, 2001, at the effective time of the Merger (the "Effective Time"), Merger Sub was merged with and into Rosetta and Rosetta became a wholly-owned subsidiary of Merck, pursuant to the terms and conditions of the Merger Agreement. By virtue of the Merger, each share of Rosetta common stock (other than those shares held in the treasury of Rosetta or shares that were owned by Rosetta, Merck or Merger Sub) was converted into the right to receive 0.2352 shares of Merck common stock, and cash in lieu of fractional shares of Merck common stock. By virtue of the Merger, each share of the common stock of Merger Sub, par value \$0.01 per share, was converted into one share of the common stock of Rosetta. As a result of the Merger, Merck now beneficially owns 100% of the outstanding shares of Rosetta common stock.

As previously described in the Schedule 13D, simultaneously with the execution of the Merger Agreement, Merck and certain stockholders of Rosetta (collectively, the "Stockholders") entered into separate Voting and Stock Option Agreements, dated as of May 10, 2001 (the "Voting and Stock Option Agreements") pursuant to which, among other things, Merck obtained the right, upon the occurrence of certain events, to purchase upon exercise of the option 9,631,035 shares of Rosetta common stock held by the Stockholders, as well as any additional shares of Rosetta common stock acquired by the Stockholders prior to such exercise. Pursuant to the terms of the Voting and Stock Option Agreements, the Voting and Stock Option

3

4

Agreements terminated at the Effective Time. A copy of the form of Voting and Stock Option Agreements was attached to the Schedule 13D and is specifically incorporated herein by reference, and the description herein of the Voting and Stock Option Agreements is qualified in its entirety by reference to such form of Voting and Stock Option Agreements.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Edgar Filing: ROSETTA INPHARMATICS INC - Form SC 13D/A

DOCUMENT

Exhibit A - Press Release issued on July 19, 2001.

4

5

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 20, 2001

MERCK & CO., INC.

By: /s/ Celia A. Colbert

Name: Celia A. Colbert
Title: Vice President, Secretary and
Assistant General Counsel

5

6

EXHIBIT INDEX

DOCUMENT

Exhibit A - Press Release issued July 19, 2001.

6